176 followers
Ruxolitinib (JAK inhibitor) results in unrestrained TLR signalling promoting CLL cell activation driving disease progression. https://t.co/dkUb0GdIom
Ruxolitinib (JAK inhibitor) results in unrestrained TLR signalling promoting CLL cell activation driving disease progression. https://t.co/dkUb0GdIom